205 related articles for article (PubMed ID: 19142182)
1. Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Kondo M; Hoshi SL; Toi M
Br J Cancer; 2009 Jan; 100(2):281-90. PubMed ID: 19142182
[TBL] [Abstract][Full Text] [Related]
2. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
[TBL] [Abstract][Full Text] [Related]
4. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
[TBL] [Abstract][Full Text] [Related]
5. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Waters EA; McNeel TS; Stevens WM; Freedman AN
Breast Cancer Res Treat; 2012 Jul; 134(2):875-80. PubMed ID: 22622807
[TBL] [Abstract][Full Text] [Related]
6. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
[TBL] [Abstract][Full Text] [Related]
7. National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
McCaskill-Stevens W; Wilson JW; Cook ED; Edwards CL; Gibson RV; McElwain DL; Figueroa-Moseley CD; Paskett ED; Roberson NL; Wickerham DL; Wolmark N
Clin Trials; 2013 Apr; 10(2):280-91. PubMed ID: 23335675
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention for high-risk women: tamoxifen and beyond.
Fabian CJ; Kimler BF
Breast J; 2001; 7(5):311-20. PubMed ID: 11906441
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Kondo M; Hoshi SL; Toi M
Jpn J Clin Oncol; 2009 Nov; 39(11):767-70. PubMed ID: 19656807
[TBL] [Abstract][Full Text] [Related]
11. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
13. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract][Full Text] [Related]
14. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention in postmenopausal women.
Rastogi P
Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk.
Armstrong K; Chen TM; Albert D; Randall TC; Schwartz JS
Obstet Gynecol; 2001 Dec; 98(6):996-1003. PubMed ID: 11755544
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of breast cancer: implications for postmenopausal women.
Fabian CJ; Kimler BF
Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
[TBL] [Abstract][Full Text] [Related]
18. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
Anderson C; Nichols HB; House M; Sandler DP
Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
[TBL] [Abstract][Full Text] [Related]
19. Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).
Cecchini RS; Costantino JP; Cauley JA; Cronin WM; Wickerham DL; Bandos H; Weissfeld JL; Wolmark N
Cancer Prev Res (Phila); 2012 Nov; 5(11):1321-9. PubMed ID: 23060039
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer chemoprevention.
Rosenbaum Smith SM; Osborne MP
Am J Surg; 2000 Oct; 180(4):249-51. PubMed ID: 11113429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
